Patent classifications
C07D223/22
Oxalic amide ligands, and uses thereof in copper-catalyzed coupling reaction of aryl halides
The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of CN, CO and CS bonds. ##STR00001##
Oxalic amide ligands, and uses thereof in copper-catalyzed coupling reaction of aryl halides
The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of CN, CO and CS bonds. ##STR00001##
COMPOUND FOR INHIBITION OF DELTA-5-DESATURASE (D5D) AND TREATMENT OF CANCER AND INFLAMMATION
Tricyclic compounds, including tricyclic iminodibenzylic and tricyclic iminostilbene compounds, are identified as therapeutic agents for inhibition of delta-5-desaturase (D5D) and for treating or preventing cancer and precancerous conditions, as well as autoimmune and inflammatory conditions. Pharmaceutical compositions and dietary supplements are provided, as are methods of administration and treatment.
MATERIALS FOR ELECTRONIC DEVICES
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.
MATERIALS FOR ELECTRONIC DEVICES
The present invention relates to compounds according to formula (I), which are suitable for use in electronic devices, preferably organic electroluminescent devices.
Substituted dibenzo[b, f]azepines as proteasome activators
The disclosure is directed to substituted dibenzo[b,f]azepines of the formula (II): ##STR00001## wherein the variables n, X.sup.3, R.sup.1, R.sup.2, R.sup.4, and R.sup.5 are defined herein, and uses of such compounds to treat conditions including neurodegenerative diseases and cancers.
OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE
The present invention provides oxalic amide ligands and uses thereof in copper-catalyzed coupling reaction of aryl halides. Specifically, the present invention provides a use of a compound represented by formula I, wherein definitions of each group are described in the specification. The compound represented by formula I can be used as a ligand in copper-catalyzed coupling reaction of aryl halides for the formation of CN, CO and CS bonds.
##STR00001##
NOVEL CRYSTALLINE FORM OF ESLICARBAZEPINE
The present invention provides novel crystalline form L1 of eslicarbazepine characterized by diffraction peaks at 7.09, 10.03, 11.73, 14.12, 16.94, 18.03, 20.00, 23.20, 23.58, 23.76, 26.05, 26.52, 28.37, 29.90, 31.420.2 degree two theta in an X-ray diffraction pattern. The present invention further provides conversion of crystalline form L1 of eslicarbazepine to eslicarbazepine acetate.
NOVEL CRYSTALLINE FORM OF ESLICARBAZEPINE
The present invention provides novel crystalline form L1 of eslicarbazepine characterized by diffraction peaks at 7.09, 10.03, 11.73, 14.12, 16.94, 18.03, 20.00, 23.20, 23.58, 23.76, 26.05, 26.52, 28.37, 29.90, 31.420.2 degree two theta in an X-ray diffraction pattern. The present invention further provides conversion of crystalline form L1 of eslicarbazepine to eslicarbazepine acetate.
Biocatalytic process for preparing eslicarbazepine and analogs thereof
The present disclosure relates to biocatalysts and its uses for the efficient preparation of eslicarbazepine, eslicarbazepine acetate, and analogs thereof.